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Abstract Aim of this study was to explore influence of the
quadrivalent HPV vaccine (Gardasil) on the immune
status of recurrent respiratory papillomatosis (RRP)
patients. In retrospective observational study, six RRP
patients who received the quadrivalent HPV vaccine and
whose HPV seroreactivity was measured were included.
Multiplex HPV Serology was used to determine HPV-
specific antibodies pre- and post-vaccination. Surgical
interventions and patient records were analyzed. Five
HPV6 and 1 HPV11 infected patient were included. Mean
antibody reactivity against the associated HPV type rose
from 1125 median fluorescence intensity (MFI) pre-vac-
cination to 4690 MFI post-vaccination (p\ 0.001). Med-
ian post-vaccination follow-up was 4 years. Poisson
regression analysis showed that the quadrivalent HPV
vaccine decreased the incidence rate of surgeries. The
immune system of RRP patients is able to increase anti-
body reactivity against the associated HPV type. A double
blind randomized controlled trial is needed to determine
whether this immunological increase can cause decrease in
number of surgeries.
Keywords Recurrent respiratory papillomatosis 
Vaccine  Therapeutic drug  Immunology
Introduction
Infection with a subset of human papillomaviruses (HPV)
can cause anogenital cancer, oropharyngeal cancer,
condylomata acuminata and recurrent respiratory papillo-
matosis (RRP) [1, 2]. Since 2006 many national vaccina-
tion programs have started with the bivalent HPV vaccine
(Cervarix, GlaxoSmithKline Biologicals s.a., Rixensart,
Belgium) or the quadrivalent HPV vaccine (Gardasil,
Merck & co, Whitehouse Station, USA) targeting high-risk
oncogenic HPV types 16 and 18. Papillomavirus vaccines
are generally safe and highly effective [3]. The quadriva-
lent HPV vaccine is a subunit vaccine composed of the
major capsid protein L1 primarily in the form of virus-like
particles (VLPs) of low-risk HPV6 and 11 and high-risk
HPV16 and 18. HPV6 and 11 cause 90 % of genital warts
[4]. It is expected that preventive global use of this HPV
vaccine against cervical cancer will decrease the incidence
of HPV6 and HPV11 related disease worldwide [5].
Recurrent respiratory papillomatosis (RRP) is a wart-
like disease characterized by its unpredictable clinical
course. It is associated with HPV6 and 11 for 80–100 % of
cases [6–10]. Therapy focuses on repeated surgical
removal of exophytic lesions. Some patients may need over
R. E. A. Tjon Pian Gi and M. R. M. San Giorgi contributed equally to
this work.
& Frederik G. Dikkers
f.g.dikkers@umcg.nl
1 Department of Otorhinolaryngology/Head and Neck Surgery,
University of Groningen, University Medical Center
Groningen, P.O. Box 30.001, 9700 RB Groningen,
The Netherlands
2 Division of Molecular Diagnostics of Oncogenic Infections,
German Cancer Research Center, Heidelberg, Germany
3 Department of Pathology, University of Groningen,
University Medical Center Groningen, Groningen,
The Netherlands
4 Department of Mathematics and Computer Science,
Eindhoven University of Technology, Eindhoven,
The Netherlands
5 Graduate School of Medical Sciences (Cancer Research
Center Groningen), University of Groningen, Groningen,
The Netherlands
123
Eur Arch Otorhinolaryngol (2016) 273:3231–3236
DOI 10.1007/s00405-016-4085-3
a 100 surgical interventions to keep the airway open and
the voice sufficient [6].
Antibody response after vaccination with the quadriva-
lent HPV vaccine is higher than after natural infection in
patients with high-risk HPV [3, 11]. Little is known about
the antibody response for low-risk HPV. Increased
seroreactivity after vaccination in RRP patients was only
addressed in two case reports [12, 13]. After vaccination
with the quadrivalent HPV vaccine, HPV seropositive
women were protected against cervical and anogenital
diseases from the corresponding HPV type [3]. Therefore,
vaccination of RRP patients could be a potential treatment
against HPV re-infection or auto-inoculation. In this
independent exploratory study we investigated whether
vaccination with the quadrivalent HPV vaccine results in
increase of antibodies against the associated viruses.
Materials and methods
Ethical considerations
Patients included in this retrospective cohort study were
clinically treated off-label with the quadrivalent HPV
vaccine; there was no scientific intent. Due to great inter-
national interest in the use of this therapy, it was decided to
publish these valuable data. Written approval of all patients
was received.
Institutional Review Board approval for retrospective
cohort research is not needed in The Netherlands. All
patients approved use of information from their patient
files, laboratory results and biopsy material, by signing a
consent form.
Biopsy and resection material of the included patients
were available in archives of our Department of Pathology.
This study was performed according to the Code of Con-
duct for Proper Secondary Use of Human Tissue in The
Netherlands, as well as to the applicable institutional and
national guidelines [14].
Patients
Patients’ charts and surgical reports of all RRPpatients treated
at the Department of Otorhinolaryngology/Head and Neck
Surgery of the tertiary referral hospital University Medical
Center Groningen, University of Groningen, The Netherlands
were retrospectively analyzed. Inclusion criteria for this study
were: (1) histological confirmation of RRP by an experienced
head and neck pathologist, (2) the patient received the
quadrivalent HPV vaccine with therapeutic intent, (3) HPV
seroreactivity known pre- and post-vaccination.
Patient charts were reviewed on date of birth, gender,
date of diagnosis, risk factors (gastroesophageal reflux
disease (GERD) and asthma), follow-up, number of surg-
eries, complications of administration of the quadrivalent
HPV vaccine and complications associated with RRP
(carcinoma, tracheotomy). Patients with an age of onset
younger than 18 years of age have juvenile onset RRP
(JoRRP). Patients older than 18 years at onset of disease
have adult onset RRP (AoRRP).
Vaccination
The quadrivalent HPV vaccine was clinically administered
to RRP patients between March 2011 and January 2013.
Vaccination was injected intramuscularly by normal
dosage of VLP6 20 lg, VLP11 40 lg, VLP16 40 lg, and
VLP18 20 lg per injection (0.5 ml). Injections were given
following the same schedule as in preventive vaccination:
at 0, 2 and 6 months [15]. The time after the first admin-
istration was considered as ‘post-vaccination’. The second
and third vaccinations were administered for durability of
the effect [15].
Time frame
A blood sample was taken immediately before the first
injection of the quadrivalent HPV vaccine (pre-vaccination
seroreactivity). A second blood sample was taken imme-
diately before the third vaccination (representing post-
vaccination seroreactivity).
Patient material
HPV type specific polymerase chain reaction (PCR)
For each patient a stored paraffin block from the first for-
malin-fixed biopsy was selected, in which papilloma was
histopathologically confirmed. To confirm presence of
papilloma an experienced pathologist revised all biopsies.
When quality or quantity of the first biopsy was not suf-
ficient for PCR, the next sufficient biopsy was used. HPV
typing was performed using the HPV consensus primer set
GP5?/6? with subsequent nucleotide sequence analysis.
Details of this technique have been described before [6].
Antibody seroreactivity
Seroreactivity to the HPV major capsid L1 protein for both
HPV6 and HPV11 was measured to monitor antibody
response against the quadrivalent HPV vaccine. Blood
samples were analyzed by the multiplex human papillo-
mavirus serology, based on in situ-purified glutathione
S-transferase proteins, as described by Waterboer et al. [16,
17]. Briefly, full-length L1 proteins were bacterially
expressed as fusion proteins with N terminal glutathione-S-
3232 Eur Arch Otorhinolaryngol (2016) 273:3231–3236
123
transferase (GST) and a C terminal tagging peptide (tag) and
were affinity-purified in situ from cleared bacterial lysates
through binding to glutathione casein-coated fluorescence-
labeled polystyrene beads. A fusion protein consisting of
GST and tag (GST-tag) without intervening viral antigen
served for background determination. Each fusion protein
was bound to a spectrally distinct bead set. Fusion protein-
loaded bead sets were mixed. Sera were pre-incubated at
1:50 dilution in PBS containing 1 mg/mL casein, 2 mg/mL
lysate from bacteria expressing GST-tag alone to block
antibodies directed against residual bacterial proteins and
GST-tag, 0.5 % polyvinylalcohol (PVA, Sigma-Aldrich
Chemie Gmbh Munich, Germany), 0.8 % polyvinylpyrroli-
done (PVP, Sigma-Aldrich Chemie Gmbh Munich, Ger-
many) and 2.5 % Superchemiblock (Millipore, Billerica,
MA, USA) to suppress unspecific binding of antibodies to
the beads themselves [17]. Serum dilutions were incubated
with the same volume of mixed bead sets, resulting in a final
serum dilution of 1:100. Bound antibodies were detected
with biotinylated goat-antihuman IgG (H ? L) secondary
antibody and streptavidin-R-phycoerythrin. A Luminex
analyser (xMAP, Luminex Corp., Austin, TX, USA) was
used to identify the internal color of the individual beads and
to quantify their reporter fluorescence (expressed as median
fluorescence intensity (MFI) of at least 100 beads per set per
serum). Antibody reactivity, i.e. the amount of antigen-
specific antibody bound per bead is expressed as net MFI
values calculated as difference of MFI with HPV-protein
minus MFI with GST-tag.
Statistical analysis
Analyses were performed using PASW statistics version
20.0 (SPSS Inc., Chicago, IL, USA) and SAS version 9.3
(SAS Institute, Inc., Cary, NC, USA).
Categorical variables are presented as number (per-
centage). Normally distributed variables are presented as
mean ± standard deviation. Data presented as [x; x] repre-
sents 95 % confidence interval. p value of \0.05 was
considered statistically significant.
A paired t test was used to analyze the difference
between pre- and post MFI. Descriptive statistics were
provided for the rate of surgical interventions (number of
surgical interventions divided by time interval) before and
after vaccinations. A Spearman correlation coefficient
between the two rates was calculated. Poisson regression
analysis (with a random intercept for subjects) was applied
to investigate a possible effect of vaccine on the mean
number of surgical interventions corrected for type of
papilloma virus (HPV6 and HPV11) and age at onset.
Subject’s variable log time period was included in the
regression analysis as offset parameter to adjust for dif-
ferent time intervals for subjects.
Since the analysis is only preliminary and exploratory, a
sample size for a parallel group randomized clinical trial
was calculated on the basis of an effect size that vaccina-
tion reduces the mean number of surgical interventions
with 50 %. Formula four of Signorini et al. with a Ber-
noulli covariate was used [18].
Results
Nine RRP patients of the University Medical Center
Groningen received the quadrivalent HPV vaccine. For six
of them seroreactivity pre- and post-vaccination were
known; these six patients were included in this exploratory
study. Patients were diagnosed with RRP between 1981
and 2011, followed until August 1, 2015. Characteristics
per patient are presented in Table 1. All included patients
were male. The mean age of onset was 16 years (SD 16).
Three patients (50 %) had JoRRP, three patients (50 %)
had AoRRP. None of the patients had asthma or GERD.
Five patients were infected with HPV6 and one patient was
infected with HPV11.
The mean pre-vaccination antibody reactivity was 1125
MFI (SD 884). The mean post-vaccination antibody reac-
tivity was 4690 MFI (SD 727). All individual antibody
reactivities increased after vaccination, with a median rise
of 3766 MFI (range 1199–4670). The mean MFI per
patient rose significantly after vaccination (p\ 0.001). The
change of pre- and post-vaccination antibody reactivity of
the associated viruses are represented in Fig. 1.
None of the patients experienced side effects or com-
plications of the vaccination. The surgical course over time
is presented in Fig. 2. The median pre-vaccination disease
history was 3 years (range 1–30). The median post-vacci-
nation follow-up was 4 years (range 3–4). The interval
between surgeries ranged from 1 week to 7 years (Fig. 2).
The average rates of surgical interventions for a period of a
year were 4.34 [1.11; 7.57] and 0.99 [0.25; 1.73] before
and after vaccination, respectively. Spearman correlation
coefficient between the rates before and after was estimated
at -0.20 (p = 0.704).
Poisson regression analysis corrected for age at onset
and type of HPV demonstrated a clinical effect of vacci-
nation. The effect size was estimated at -1.20 [-1.90;
-0.50]. This meant that the mean number of surgical
interventions in a specific time frame after vaccination
decreased with approximately a factor of 3.3 (=exp1.20).
Based on the results of a simpler Poisson regression
analysis (using only the vaccination variable and overdis-
persion), the sample size for detecting reduction in the
mean number of surgical interventions after vaccination
with a factor of 2 was calculated. If a theoretical trial
period would be 1 year, the total number of patients in each
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group should be 57. If a trial would be extended to
1.5 years, the number of patients in each group should be
38, while for a trial of 2 years the number of patients
should be 29 in each group.
Discussion
Many therapies have been tried to diminish disease burden
of RRP. Nonetheless there is still no curative therapy for
RRP patients. The primary goal of this exploratory study
was to monitor effectiveness of the quadrivalent HPV
vaccine during treatment of RRP as determined by
increased seroreactivity. This is the first study that shows
that vaccination of a group of RRP patients with the
quadrivalent HPV vaccine results in increased seroreac-
tivity against associated viruses.
Five of six patients were infected with low-risk HPV6,
one was infected with low-risk HPV11. The ratio between
HPV6 and HPV11 differs per cohort [19], probably
because of geographical spread of both viruses [20]. This
research consisted of both JoRRP and AoRRP patients.
The immunological response is therefore representable for
both groups. A difference in immune response is not
expected. RRP patients with a pre-vaccination history of
1–30 years were included.
The presented data show that RRP patients with HPV6
and HPV11 have low levels of seroreactivity against these
viruses despite many years of disease. After administration
of the quadrivalent HPV vaccine HPV seroreactivity
against the causal HPV type rose in every patient. The
vaccination induced higher seroreactivity than the natural
infection in the same patients. Theoretically this induced




















































































































































































































































































































































































































































































































































































Fig. 1 Antibody reactivity per patient against the associated HPV
type pre- and post-vaccination (#1 HPV11 patient, #2–#6 HPV6
patients)
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course of RRP by intensifying immune response and pre-
venting re-infection.
This study is the first study to measure seroreactivity in a
group of RRP patients. Results could be biased due to the
small sample size and short follow-up. An effect of other
adjuvant therapy on immunological response was not
expected as patients did not receive any adjuvant therapy
1 month before, neither during or after vaccination. More
research is needed to analyze the duration of the
immunological response.
Chirila et al. concluded that the quadrivalent HPV
vaccine was effective to diminish the recurrence rate of
RRP in 85 % of patients, although that study was retro-
spective and lacked a control group [21]. Furthermore the
natural decreasing surgical rate of RRP was not taken into
account [6, 22]. It is unknown if there is a immune
response after vaccination which explains a clinical
response, therefore this study was conducted. The clinical
response described in this article was only used for a power
analysis for a future randomized controlled trial (RCT), as
the sample size was too small to analyze the clinical course
and to correct for the natural clinical course and other
therapies (e.g. cidofovir). A RCT is needed to draw con-
clusions on the real clinical effect of the quadrivalent HPV
vaccine. The proposed sample size for a trial with a follow-
up of 2 years should be 29 patients per group.
Conclusion
RRP patients increase seroreactivity against the quadriva-
lent HPV vaccine, regardless of their age, age of onset,
HPV type and severity of disease. Antibody reactivities to
the associated viruses of all patients rose significantly. A
double-blinded randomized controlled trial is needed to
evaluate the effect of this vaccination on the clinical
course. The quadrivalent HPV vaccine could be of future
help in the treatment of RRP, as this research showed that
vaccination causes a robust immunological response.
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